Upstream Bio Inc (UPB) — Titan Protect Analysis

UPB

Upstream Bio Inc

Healthcare · ·

$7.05

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$409M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-2.49

Based on estimated future earnings — lower means cheaper

Rev Growth

+82.7%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-41.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$42.00

+496% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 7 analysts covering this stock

About Upstream Bio Inc

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

https://upstreambio.com

Country: United States Employees: 75 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.207

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0328

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.623

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-48.5%

Historical annualised return based on price data

Max Drawdown

-77.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$33.68

79% below the year high

52W Low

$7.19

-2% above the year low

Avg Volume

699,955

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.90

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.37

Conservative use of debt — low financial risk

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-4,218.1%

Profit from core operations before interest and tax

Free Cash Flow

$-90,310,872

Negative — the business is spending more than it generates

Revenue (TTM)

$3M

Total revenue over the last 12 months

Net Income

$-156,764,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$75.00

Target Median

$42.00

Target Low

$15.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go